Gonzalo Florido
Internal Medicine · Kentland, INNPI 1063552990
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 35.4% of the total. Reporting peaked in 2021 at $1,305 and has fallen 90.2% since, to $128 in 2025. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $28.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Biohaven Pharmaceuticals, Inc.$714
- Bayer$503
- Novo Nordisk$416
- Novartis$287
- Biohaven Pharmaceutical Holding Company Ltd.$200
- plus $1K from 21 others
What the payments were for
- Food & beverage$5,31898%
- Education$862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $1,911 |
| Biohaven Pharmaceuticals, Inc. | 8 | $714 |
| Bayer | 28 | $503 |
| Novo Nordisk | 13 | $416 |
| Novartis | 13 | $287 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $200 |
| Sanofi-aventis U.S. LLC | 6 | $173 |
| Astellas Pharma US Inc | 7 | $152 |
| Boehringer Ingelheim | 8 | $138 |
| AbbVie(2 entities) | 7 | $120 |
| Lilly USA, LLC | 5 | $106 |
| Pfizer | 7 | $104 |
| Mylan Specialty L.p. | 6 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $70 |
| Merck | 4 | $70 |
| Biogen | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 3 | $52 |
| Amgen | 2 | $47 |
| Dexcom, Inc. | 3 | $43 |
| Johnson & Johnson | 2 | $30 |
| Sanofi Pasteur Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Pulmonx Corporation | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Abbott | 1 | $12 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,404 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 165 | $67,267 |
| FarxigaDapagliflozin Propanediol | 73 | $57,950 |
| Bydureon BciseExenatide Microspheres | 29 | $46,952 |
| OzempicSemaglutide | 31 | $40,335 |
| TradjentaLinagliptin | 85 | $34,012 |
| TrulicityDulaglutide | 34 | $30,421 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $22,342 |
| JardianceEmpagliflozin | 22 | $19,782 |
| VraylarCariprazine Hcl | 11 | $15,637 |
| MounjaroTirzepatide | 13 | $13,608 |
| XareltoRivaroxaban | 32 | $11,763 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,507 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,377 |
| Potassium Chloride | 263 | $7,313 |
| Memantine Hcl | 135 | $6,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $104 | $67,267165 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,911 | $66,32786 claims |
| Boehringer IngelheimTradjenta, Jardiance | $138 | $53,794107 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $106 | $44,02947 claims |
| Novo NordiskOzempic | $416 | $40,33531 claims |
| AbbVieVraylar | $120 | $15,63711 claims |
| Johnson & JohnsonXarelto | $30 | $11,76332 claims |
| Astellas Pharma US IncMyrbetriq | $152 | $4,79521 claims |
| Sanofi-aventis U.S. LLCLantus | $173 | $3,14613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Kentland
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Emily FrankLebanon$100K
- David IloFort Wayne$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.